US Bancorp DE Purchases 12,955 Shares of Cardinal Health, Inc. $CAH

Key Points

• US Bancorp DE raised its stake in Cardinal Health by 32.4%, acquiring 12,955 shares in Q4 to hold 52,992 shares worth about $10.89 million.
• Cardinal Health beat Q3 EPS ($3.17 vs. $2.79) and raised FY‑2026 guidance to $10.70–$10.80 and executed additional buybacks, but revenue missed expectations (~$60.94B vs. $62.1B) and a $184M goodwill impairment hurt GAAP results, leaving the report mixed.

US Bancorp DE raised its position in Cardinal Health, Inc. (NYSE:CAH - Free Report) by 32.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 52,992 shares of the company's stock after acquiring an additional 12,955 shares during the quarter. US Bancorp DE's holdings in Cardinal Health were worth $10,890,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Fagan Associates Inc. bought a new position in Cardinal Health in the fourth quarter valued at about $260,000. Simplicity Wealth LLC lifted its holdings in Cardinal Health by 18.4% in the fourth quarter. Simplicity Wealth LLC now owns 1,857 shares of the company's stock valued at $382,000 after acquiring an additional 289 shares during the period. Keybank National Association OH lifted its holdings in Cardinal Health by 11.0% in the fourth quarter. Keybank National Association OH now owns 18,595 shares of the company's stock valued at $3,821,000 after acquiring an additional 1,840 shares during the period. Wealthfront Advisers LLC raised its stake in shares of Cardinal Health by 7.5% in the fourth quarter. Wealthfront Advisers LLC now owns 57,299 shares of the company's stock worth $11,775,000 after buying an additional 4,015 shares during the period. Finally, Torren Management LLC bought a new position in shares of Cardinal Health in the fourth quarter worth about $44,000. Institutional investors own 87.17% of the company's stock.

Cardinal Health Trading Up 1.2%

NYSE:CAH opened at $195.13 on Friday. Cardinal Health, Inc. has a 12-month low of $137.75 and a 12-month high of $233.60. The stock has a 50-day moving average price of $213.73 and a 200 day moving average price of $205.82. The stock has a market capitalization of $45.92 billion, a P/E ratio of 29.84, a P/E/G ratio of 1.20 and a beta of 0.53.

Cardinal Health (NYSE:CAH - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.38. Cardinal Health had a negative return on equity of 92.61% and a net margin of 0.62%.The firm had revenue of $60.94 billion during the quarter, compared to analysts' expectations of $62.10 billion. During the same quarter last year, the business posted $2.35 earnings per share. The firm's revenue was up 11.0% on a year-over-year basis. Cardinal Health has set its FY 2026 guidance at 10.700-10.80 EPS. On average, research analysts predict that Cardinal Health, Inc. will post 10.76 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st were given a dividend of $0.5107 per share. The ex-dividend date was Wednesday, April 1st. This represents a $2.04 annualized dividend and a dividend yield of 1.0%. Cardinal Health's dividend payout ratio (DPR) is currently 29.35%.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q3 non‑GAAP earnings beat estimates and company raised FY‑2026 guidance to $10.70–$10.80, above consensus — the core bullish catalyst. PR Newswire: Q3 Results & Outlook
• Positive Sentiment: Company executed $250M additional share repurchase (bringing FY26 repurchases to $1.0B) and reduced debt — shareholder‑friendly actions that support the share price. PR Newswire: Buybacks & Debt Reduction
• Neutral Sentiment: Wells Fargo cut its price target from $256 to $245 but kept an "overweight" rating, signaling continued analyst confidence despite the trim. Benzinga: Wells Fargo PT Change
• Neutral Sentiment: Full earnings call and transcripts are available for investors who want details on segment performance and management commentary. Yahoo Finance: Earnings Transcript Seeking Alpha: Call Transcript
• Negative Sentiment: Revenue missed expectations ($60.9B reported vs. ~$62.1B est.), which prompted media coverage and short‑term selling pressure despite the EPS beat. Benzinga: Revenue Miss Coverage
• Negative Sentiment: GAAP results were weaker: GAAP operating earnings and GAAP EPS declined, driven in part by a $184M pre‑tax goodwill impairment in the Navista & ION reporting unit — a one‑time charge that reduces headline profitability. PR Newswire: Goodwill Impairment
• Negative Sentiment: Several outlets highlighted the "mixed" nature of the report (EPS/guidance vs. revenue/GAAP weakness), which can increase volatility and keep some investors on the sidelines. CNBC: Mixed Results Coverage

Analyst Upgrades and Downgrades

Several research firms have recently commented on CAH. Mizuho raised their price objective on Cardinal Health from $222.00 to $235.00 and gave the stock an "outperform" rating in a research note on Friday, February 6th. Evercore decreased their price objective on Cardinal Health from $260.00 to $240.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 8th. Barclays raised their price objective on Cardinal Health from $243.00 to $258.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. raised their price objective on Cardinal Health from $209.00 to $243.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 10th. Finally, Zacks Research raised Cardinal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Cardinal Health has a consensus rating of "Moderate Buy" and a consensus price target of $243.67.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.